Esprit BTK Everolimus Eluting Resorbable Scaffold System
ABBOTT MEDICAL · Decision date Jul 25, 2025
What did the FDA decide?
FDA records P230036/S012 as a supplement to PMA P230036, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 25, 2025.
FDA approval order statement
to remove an in-process moisture content inspection step for tube extrusion
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Jul 25, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230036/S012
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- NXW
- Decision code
- OK30
- Decision date
- Jul 25, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Scaffold, infrapopliteal, absorbable.
- Applicant
- Abbott Medical
- Product code
- NXW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230036. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230036 · Original PMA
Esprit BTK Everolimus Eluting Resorbable Scaffold System
P230036/S012 received
Application receipt date recorded by FDA.
P230036/S012 · FDA decision
30-Day Notice
P230036/S013 · Related supplement
Esprit BTK Everolimus Eluting Resorbable Scaffold System
P230036/S014 · Related supplement
Esprit BTK Everolimus Eluting Resorbable Scaffold System
P230036/S015 · Related supplement
Esprit BTK Everolimus Eluting Resorbable Scaffold System
P230036/S016 · Related supplement
Esprit BTK RX System; Esprit BTK OTW System
P230036/S018 · Related supplement
Esprit BTK Everolimus Eluting Resorbable Scaffold System
P230036/S017 · Related supplement
Esprit BTK Everolimus Eluting Resorbable Scaffold System
P230036/S020 · Related supplement
Esprit BTK Everolimus Eluting Resorbable Scaffold System
Timeline entries are records held by MedtechLedger for P230036. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230036
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | Apr 26, 2024 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Aug 8, 2025 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Aug 29, 2025 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 26, 2025 | FDA | |
Esprit BTK RX System; Esprit BTK OTW SystemP230036/S016 | ABBOTT MEDICAL | PMA supplement | Oct 22, 2025 | FDA |
| ABBOTT MEDICAL | PMA supplement | May 22, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Jul 9, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 24, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 3200 Lakeside Dr., Santa Clara, CA, 95054
Sources and methodology
- Original FDA record: P230036/S012
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




